Description

PA007167.r2b: Recombinant Anti-Mouse CD8a (2.43) Antibody , Rat IgG2b Kappa, In Vivo Grade

Background

The rat anti-mouse CD8a monoclonal antibody 2.43 (rat IgG2b kappa) reacts with the mouse CD8a protein (T-cell surface glycoprotein CD8 alpha chain) encoded by the mouse CD8A gene that encodes the CD8a chain of the dimeric CD8 protein. The mouse CD8 protein is primarily responsible for cell-mediated immune defense and T-cell development. CD8A has been widely reported as a potential prognosis and diagnostic marker for several diseases, such as inflammatory disorders and tumors. It was shown that the anti-mouse CD8a rat monoclonal antibody (clone number: 2.43) can be used for depleting activity in vivo.

Our recombinant YTS 169.4 antibodies have a part (variable regions) or complete amino acid sequences of the rat anti-mouse CD8a monoclonal antibody (hybridoma clone name or number: 2.43).

The in vivo grade recombinant anti-mouse CD8a rat IgG2b monoclonal antibody was produced in mammalian cells.

References for Anti-Mouse CD8a Monoclonal Antibody (Clone: 2.43)

1. Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses.
Balogh, K. N., et al. PLoS One. 2018 Jun 4;13(6):e0197702. PMID: 29864117
“Mice were treated with an initial dose of 200 µg of anti-CD8 (clone 2.43) antibody in PBS, followed by 100 µg every 4 days. This study demonstrates the efficacy of clone 2.43 in sustained in vivo depletion protocols, confirming its reliability in tumor growth inhibition assays.”

2. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
Voron, T., et al. J Exp Med. 2015 Feb 9;212(2):139-48. PMID: 25601652
“For CD8+ T cell depletion, anti-CD8 antibody (clone 2.43) was administered at 100 µg i.p. to CT26-tumor bearing mice. The depletion efficiency was validated via flow cytometry, confirming clone 2.43 as a gold-standard reagent for verifying T cell checkpoint functionality.”

3. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells.
Li, J., et al. Immunity. 2018 Apr 17;48(4):773-786.e5. PMID: 29625896
“To deplete CD8+ T cells in the A20 tumor model, 100 µg of anti-CD8 (clone 2.43) was injected i.p. on a strategic schedule (Day -1, 2, 7, 12, 17). This robust protocol achieved depletion efficiencies of up to 85%, providing clear evidence of clone 2.43’s utility in multi-dose, long-term in vivo experimental designs.”

Frequently Asked Questions (FAQ) about Recombinant Anti-Mouse CD8a Antibody (Clone: 2.43)

Question: Can I use clone 2.43 for in vivo CD8+ T cell depletion?
Answer: Yes, clone 2.43 is the gold-standard antibody for in vivo CD8+ T cell depletion in mouse models. Syd Labs provides a recombinant, sequence-defined, low-endotoxin version of clone 2.43, engineered to ensure high depletion efficiency (>90%) with minimal non-specific immune activation.

Question: What is the recommended mouse CD8+ T cell depletion protocol and clone 2.43 injection dosage in vivo?
Answer: For an optimal mouse CD8+ T cell depletion protocol, typical dosage ranges from 100 µg to 500 µg per mouse per intraperitoneal (i.p.) injection, depending on your specific model (e.g., tumor suppression vs. viral infection). Consistency in injection frequency (e.g., every 3-4 days) is key to maintaining sustained depletion levels. Please refer to our “References” section for validated protocols utilized in published experimental models.

Question: Do I need an isotype control when using clone 2.43 for depletion?
Answer: Yes, incorporating an isotype control is critical to distinguish target-specific depletion effects from Fc-receptor-mediated background noise. We strongly recommend using our highly purified rat IgG2b or mouse IgG2a isotype controls, precisely matching the isotype of your selected 2.43 product, to ensure your experimental readouts are statistically robust and publication-ready.

Question: Why choose recombinant 2.43 over traditional hybridoma-derived antibodies?
Answer: Traditional hybridoma lines are highly susceptible to genetic drift, chromosomal loss, and inherent batch-to-batch variation. Syd Labs’ recombinant anti-mouse CD8a 2.43 is produced in mammalian cells, ensuring absolute sequence consistency. This advanced platform guarantees ultra-low endotoxin levels (<1 EU/mg), eliminating the toxicity often seen with traditional hybridoma formats and making it the superior choice for reproducible research.

Question: How do I verify CD8 depletion efficiency in my mouse model?
Answer: The most widely accepted standard approach is to perform Flow Cytometry (FC) analysis on peripheral blood, spleen, or lymph node cell suspensions 24-48 hours after the initial injection. Important: You must use a different non-competing anti-CD8a clone (such as clone 53-6.7) for your fluorescent staining to accurately quantify the remaining T cells without competitive interference from the depleting 2.43 antibody.

Question: How should I cite this antibody in my research publication?
Answer: When publishing your research using this product, please cite our antibody as: “Recombinant Anti-Mouse CD8a Monoclonal Antibody (Syd Labs, Cat# PA007167.r2b; RRID: AB_3697157).” (Note: If using the mouse IgG2a variant, please update the Cat# to PA007167.m2a).